Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Combined EMS and RF Treatments

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04124419
Recruitment Status : Recruiting
First Posted : October 11, 2019
Last Update Posted : October 11, 2019
Sponsor:
Information provided by (Responsible Party):
InMode MD Ltd.

Brief Summary:
The objective of this trial is to evaluate the safety and efficacy of the Evolve device utilizing the Ti10 and Tone applicators for abdominal non-invasive circumference reduction and skin tightening

Condition or disease Intervention/treatment Phase
Non-invasive Circumference Reduction Device: Treatment with Evolve System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Baseline Controlled Study to Evaluate the Safety and Efficacy of Combined EMS and RF Treatments for Non-Invasive Circumference Reduction and Skin Tightening
Actual Study Start Date : July 19, 2019
Estimated Primary Completion Date : July 19, 2020
Estimated Study Completion Date : July 19, 2020

Arm Intervention/treatment
Experimental: Treatment Arm
Eligible subjects will receive up to 3 treatments (2-week interval) with the Evolve device utilizing the Ti10 and Tone applicators according to the study protocol.
Device: Treatment with Evolve System
EMS and RF Treatment




Primary Outcome Measures :
  1. Change in circumference reduction [ Time Frame: 1 month, 3 month, 6 months ]
    statistical difference in circumference reduction between Control (baseline measurement) and three points of follow-up measurement: 4 weeks (1Month) 12 weeks (3Month) and 24 weeks (6 months) following the last Tx session.

  2. Change in skin appearance [ Time Frame: 1 month, 3 month, 6 months ]

    Improvement in skin appearance comparing pre and at 1, 3 months and 6 months post last treatment photographs (as assessed by blinded investigators):

    Success is defined by correct identification of the pre and post-treatment photos as demonstrated in at least 70% or greater of patients completed the treatment at 1 month, 3 months, and 6 months post-treatment.


  3. Change in abdomen area appearance assessed by 3D Photographic analysis [ Time Frame: 1 month, 3 month, 6 months ]
    3D Photographic analysis will be conducted using QuantifiCare System at follow up visits and compared to the baseline.

  4. Change in abdomen area appearance assessed by Investigator [ Time Frame: 1 month, 3 month, 6 months ]
    - Investigator assessment of the skin appearance comparing pre and post treatment using 0 - 4 -points Likert scale at follow up visits: 4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference


Secondary Outcome Measures :
  1. Subject Improvement assessment [ Time Frame: 1 Month, 3 Months, 6 Months ]

    Improvement assessment will be performed independently by the subject himself using 4 points Likert scale questionnaire (Global Aesthetic Improvement Scale), as follows:

    4 = Significantly marked improvement; 3 = Marked improvement; 2 = Moderate improvement; 1 = Slight improvement; 0 = No difference.


  2. Subject satisfaction assessment [ Time Frame: 1 month, 3 months, 6 months ]

    Subject assessment of satisfaction will be filled out by subjects using a 5-points Likert scale, as follows:

    +2 = Very satisfied; +1 = Satisfied; 0 = Indifferent; -1 = Disappointed; -2 = Very disappointed.


  3. Subject assessment of comfort [ Time Frame: 1 month, 3 months, 6 months ]

    Subject assessment of comfort will be filled out by subjects using a 5-point Likert scale, as follows:

    +2 = Very comfortable; +1 = Comfortable; 0 = Indifferent; -1 = uncomfortable; -2 = Pain.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • - Signed informed consent to participate in the study.
  • Female and male subjects,18 - 65 years of age at the time of enrolment
  • BMI≤ 30
  • If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
  • In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).
  • General good health confirmed by medical history and skin examination of the treated area.
  • Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
  • The patients should be willing to comply with the study procedure and schedule, including the follow up visit, and will refrain from using any other aesthetic treatment methods for the last 6 months and during the entire study period.

Exclusion Criteria:

  • - Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body.
  • Permanent implant in the treated area such as metal plates, screws and metal piercing, silicone implants or an injected chemical substance, unless deep enough in the periosteal plane.
  • Intra-dermal or superficial sub-dermal areas that have been injected with HA/collagen/fat injections or other augmentation methods with bio-material during last 6 months.
  • Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles.
  • Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Pregnancy and nursing.
  • Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, autoimmune disorders or use of immunosuppressive medications.
  • Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  • History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
  • History of bleeding coagulopathies, or use of anticoagulants in the last 10 days.
  • Any surgical procedure in the treatment area within the last 6 months or before complete healing.
  • Having received treatment with light, laser, RF, or other devices in the treated area within 3 months, or before complete healing.
  • Use of Isotretinoin (Accutane®) within 6 months prior to treatment.
  • As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04124419


Contacts
Layout table for location contacts
Contact: Maureen Abdulla 949.305.0106 maureen.abdulla@inmodemd.com
Contact: Maria Shusterman 4164589001 marias@inmodemd.com

Locations
Layout table for location information
United States, Nevada
Avance Plastic Surgery Institute Recruiting
Reno, Nevada, United States, 89511
Contact: Erez Dayan, MD    775-800-4444    info@avanceinstitute.com   
United States, New York
BodySculpt Recruiting
New York, New York, United States, 10019
Contact: Christopher Chia, MD    212-265-2724    info@bodysculpt.com   
Sponsors and Collaborators
InMode MD Ltd.

Layout table for additonal information
Responsible Party: InMode MD Ltd.
ClinicalTrials.gov Identifier: NCT04124419     History of Changes
Other Study ID Numbers: DO608715A
First Posted: October 11, 2019    Key Record Dates
Last Update Posted: October 11, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No